SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Gonzalez MJ) "

Sökning: WFRF:(Gonzalez MJ)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Khatri, C, et al. (författare)
  • Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study
  • 2021
  • Ingår i: BMJ open. - : BMJ. - 2044-6055. ; 11:11, s. e050830-
  • Tidskriftsartikel (refereegranskat)abstract
    • Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.SettingProspective, international, multicentre, observational cohort study.ParticipantsPatients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative).Primary outcome30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality.ResultsThis study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p<0.001), age >80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.6 (0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787).ConclusionsPatients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups.Trial registration numberNCT04323644
  •  
42.
  •  
43.
  •  
44.
  •  
45.
  •  
46.
  •  
47.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
48.
  •  
49.
  •  
50.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (256)
konferensbidrag (15)
forskningsöversikt (2)
Typ av innehåll
refereegranskat (242)
övrigt vetenskapligt/konstnärligt (32)
Författare/redaktör
Moreno, LA (59)
Easton, DF (58)
Wang, Q. (56)
Castillo, MJ (56)
Gonzalez-Neira, A (54)
Schmidt, MK (54)
visa fler...
Fasching, PA (54)
Milne, RL (53)
Dunning, AM (53)
Chang-Claude, J (53)
Andrulis, IL (52)
Garcia-Closas, M (52)
Nevanlinna, H (52)
Chenevix-Trench, G (52)
Czene, K (51)
Southey, MC (51)
Hamann, U (51)
Bojesen, SE (51)
Mannermaa, A (51)
Brenner, H (50)
Hall, P (50)
Bolla, MK (50)
Jakubowska, A (50)
Lubinski, J (50)
Dennis, J (49)
Giles, GG (49)
Cox, A (49)
Ruiz, JR (49)
Radice, P (48)
Couch, FJ (48)
Guenel, P (48)
Devilee, P (48)
Dork, T (48)
Pharoah, PDP (48)
Benitez, J. (47)
Peterlongo, P (46)
Margolin, S (46)
Beckmann, MW (46)
Burwinkel, B (46)
Haiman, CA (46)
Winqvist, R (46)
Hooning, MJ (46)
Lindblom, A (45)
Michailidou, K (44)
Hopper, JL (44)
Truong, T (44)
Sawyer, EJ (44)
Zheng, W. (43)
Lambrechts, D (43)
Schmutzler, RK (43)
visa färre...
Lärosäte
Karolinska Institutet (265)
Lunds universitet (52)
Uppsala universitet (41)
Göteborgs universitet (14)
Umeå universitet (14)
Stockholms universitet (8)
visa fler...
Kungliga Tekniska Högskolan (6)
Linköpings universitet (5)
Högskolan i Skövde (5)
Högskolan Dalarna (4)
Jönköping University (3)
Handelshögskolan i Stockholm (2)
Linnéuniversitetet (2)
Sveriges Lantbruksuniversitet (2)
Mittuniversitetet (1)
visa färre...
Språk
Engelska (280)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (73)
Naturvetenskap (12)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy